Key result
SSRI usage was independently associated with an increased risk of falls in older adults (OR 1.65), and the concurrence of SSRI use and frailty substantially increased this risk (OR 2.97).
Why the study?
It was unclear whether fall risk in older adults is associated with SSRI monotherapy, and whether this association is moderated by depressive disorder or frailty.
Does SSRI monotherapy increase the risk of falls in community-dwelling older adults, and is this moderated by depression or frailty?
Cohort (n=811)
No
Does SSRI monotherapy increase the risk of falls in community-dwelling older adults, and is this moderated by depression or frailty?
Odds Ratio: 1.65 (95% CI 1.26–2.15)
p-value: p=<0.001
SSRI use is independently associated with an increased risk of falls in older adults, and this risk is substantially magnified in the presence of frailty.
May warrant fall risk monitoring with SSRI use in frail older adults; leaves open causality and deprescribing benefits for RCTs.
OBJECTIVES: To evaluate whether fall risk in older adults is associated with the use of selective serotonin receptor inhibitor (SSRI) monotherapy among geriatric outpatients, and whether this association is moderated by the presence of depressive disorder and/or frailty. METHODS: Prospective cohort study with a 12-month follow-up and including 811 community-dwelling adults aged 60 or older from a university-based Geriatric Outpatient Unit. Major depressive disorder (MDD) was diagnosed according to DSM-5 criteria; subsyndromal depression as not meeting MDD criteria, but a Geriatric Depression Scale 15-item score ≥ 6 points. Frailty was evaluated with the FRAIL questionnaire. The association between SSRI use, depression, or both as well as the association between SSRI use, frailty, or both with falls were estimated through a generalized estimating equation (GEE) adjusted for relevant confounders. RESULTS: =.004). After 12 months, 179 participants had at least one fall (22.1%). SSRI use, depression as well as frailty were all independently associated with falls during follow-up. Nonetheless, patients with concurrent of SSRI usage and non-remitted depression had no higher risk compared to either remitted SSRI users or depressed patients without SSRIs. In contrast, concurrence of SSRI use and frailty increases the risk of falling substantially above those by SSRI usage or frailty alone. CONCLUSION: SSRI usage was independently associated with falls. Especially in frail-depressed patients, treatment strategies for depression other than SSRIs should be considered.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2019) conducted a cohort in Older adults (geriatric outpatients) (n=811). Selective serotonin receptor inhibitor (SSRI) vs. Nonusers of SSRIs was evaluated on Falls during 12-month follow-up (SSRI use without frailty vs no SSRI use or frailty) (OR 1.65, 95% CI 1.26-2.15, p=<0.001). SSRI usage was independently associated with an increased risk of falls in older adults (OR 1.65), and the concurrence of SSRI use and frailty substantially increased this risk (OR 2.97).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: